---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: mTOR inhibitors"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: mTOR inhibitors. Topics: Everolimus for hypoglycemia refractory to somatostatin analogs in advanced insulinoma: ENETS 2023 guidance; Everolimus: approval status, hyperglycemic effect, and adverse effects in insulinoma; Everolimus in metastatic insulinoma with refractory hypoglycemia: French multicenter series; Everolimus in malignant insulinoma: hypoglycemia control and overall survival, Mayo Clinic cohort; 2 further topics. 6 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/mtor-inhibitors"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: mTOR inhibitors

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 mTOR Inhibitors

<a id="topic-2.2.2.1.6-1"></a>

### Everolimus for hypoglycemia refractory to somatostatin analogs in advanced insulinoma: ENETS 2023 guidance

> “Everolimus is registered for progressive advanced Pan-NET and decreases insulin secretion and action.”
> “In a retrospective, multicentre series 11 out of 12 patients demonstrated swift disappearance of hypoglycaemic symptoms with a median symptom-free period of 6.5 months, although tolerance was limited.”
> “Consequently, both PRRT with 177Lu-DOTATATE and everolimus can be considered in advanced insulinoma cases with hypoglycaemia refractory to SSA, especially in those cases with concurrent progressive disease [4, C].”
> “PRRT, chemotherapy, everolimus or sunitinib should generally be reserved for SSA-refractory cases [4, B].”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.6-2"></a>

### Everolimus: approval status, hyperglycemic effect, and adverse effects in insulinoma

> “The drug is currently approved for the treatment of adult patients with advanced, progressive, and both functioning and nonfunctioning well-differentiated panNET”
> “The hyperglycemic effect of everolimus (and other mTOR inhibitors) is, therefore, a welcome side effect in the antiproliferative treatment of insulinomas”
> “Other major adverse effects of everolimus include skin rash, stomatitis, fatigue, gastrointestinal upset, pneumonitis, anemia, and opportunistic infections”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “Furthermore, everolimus has been shown to suppress insulin secretion via inhibition of the mTORC1/S6K signalling pathway causing a reduction in hypoglycaemia in patients with advanced insulinomas”

Source: [Howarth et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788970/)

<a id="topic-2.2.2.1.6-3"></a>

### Everolimus in metastatic insulinoma with refractory hypoglycemia: French multicenter series

> “Twelve patients with metastatic insulinoma and refractory hypoglycemia who were treated with everolimus between May 2007 and June 2011 were reviewed.”
> “After a median duration of 6.5 months (range 1-35+ months), median time to the first recurrence of symptomatic hypoglycemia was 6.5 months (range 0 to 35+ months).”
> “Three patients discontinued everolimus because of cardiac and/or pulmonary adverse events at 1, 1.5, and 7 months after initiation, which led to two deaths.”

Source: [Bernard et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23392213/)

<a id="topic-2.2.2.1.6-4"></a>

### Everolimus in malignant insulinoma: hypoglycemia control and overall survival, Mayo Clinic cohort

> “PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).”
> “Overall survival (OS) was longest with SSA at 84.67 months, followed by CAPTEM at 81.67 months and everolimus at 74.07 months.”

Source: [Koch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40439997/)

<a id="topic-2.2.2.1.6-5"></a>

### Everolimus label: hyperglycemia incidence

> “Hyperglycemia, hypercholesterolemia, and hypertriglyceridemia have been reported in patients taking AFINITOR/AFINITOR DISPERZ at an incidence up to 75%, 86%, and 73%, respectively.”

Source: [Afinitor prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022334s055lbl.pdf)

<a id="topic-2.2.2.1.6-6"></a>

### Manufacturer characterization of mTOR inhibitor use

> “mTOR-inhibitors are used off-label and have potentially serious side effects”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

Additional sources: [Kulke et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19129539/); [Pavel et al. (2020)](https://doi.org/10.1016/j.annonc.2020.03.304)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
